Compare CETY & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CETY | TVRD |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 12.6M |
| IPO Year | 2020 | 2013 |
| Metric | CETY | TVRD |
|---|---|---|
| Price | $0.90 | $0.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 19.5K | ★ 184.7K |
| Earning Date | 12-01-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.01 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $957,633.00 | $911,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 959.30 |
| 52 Week Low | $0.46 | $0.77 |
| 52 Week High | $2.98 | $5.69 |
| Indicator | CETY | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 44.80 | 43.90 |
| Support Level | $0.85 | $0.85 |
| Resistance Level | $1.04 | $1.09 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 45.45 | 20.86 |
Clean Energy Technologies Inc develop renewable energy products and solutions and establish partnerships in renewable energy that make environmental and economic sense. Its segments are Waste Heat Recovery Solutions - It recycle wasted heat produced in manufacturing, waste to energy and power generation. Waste to Energy Solutions - It convert waste products created in manufacturing, agriculture, wastewater treatment plants and other industries to electricity, renewable natural gas hydrogen and bio char. Engineering, Consulting and Project Management Solutions - It provide power generation, waste to energy, and heat recovery, Procurement and Construction (EPC) services to municipal and industrial customers. It generates majority of revenue from United States followed by International.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.